最近,美国人类保健服务部秘书Tommy.G.Thompson通告了食品和药品管理局(FDA)的一项新规则,该规则限制制药公司的专利名药在到期时只能有30个月的停留期,以促使安全、有效的通用名药到达消费者的过程缩短。FDA还将改变通用名药的审核程序,以提高审核速度并降低测定一种新通用名药的安全、有效而可供患者使用所花的费用。 此项规则的改变,由于避免了耗时的立法的耽搁,使通用名 Recently, Tommy G.G. Tomompson, Secretary of the Department of Human Health Services of the United States, announced a new rule of the Food and Drug Administration (FDA) that would restrict pharmaceutical companies from having a pause of only 30 months upon expiration Period to facilitate the process of reaching a consumer safely and effectively generic generic medicines shortened. The FDA will also change the generic name drug review process to speed auditing and reduce the cost of testing a new generic name drug for safe, effective and affordable patient use. This rule change, due to avoiding the delay of time-consuming legislation, makes the common name